Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients

Basic and Clinical Pharmacology and Toxicology

Volumn 100, Issue 6, 2007, Pages 383-386

  Gunes, Arzu ^a   Bilir, Erhan ^a   Zengil, Hakan ^a   Babaoglu, Melih O ^b   Bozkurt, Atila ^b   Yasar, Umit ^b  

^a GAZI UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; CYTOCHROME P450 2C9; LOSARTAN; LOSARTAN POTASSIUM; VALPROIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXCRETION; DRUG INHIBITION; DRUG URINE LEVEL; ENZYME ACTIVITY; EPILEPSY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MOLECULAR PROBE; OXIDATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; STEADY STATE; TREATMENT DURATION;

ADOLESCENT; ADULT; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ANTAGONISM; EPILEPSY; FEMALE; GENOTYPE; HUMANS; IMIDAZOLES; LOSARTAN; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; TETRAZOLES; VALPROIC ACID;

EID: 34248657974     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2007.00061.x     Document Type: Article

References (21)

1. Loscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 1999 58 : 31 59.
2. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005 77 : 1 16.
3. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in vitro and human data. Pharmacogenetics 2002 12 : 251 63.
4. Yasar U, Tybring G, Hidestrand M et al. Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos 2001 29 : 1051 6.
5. Allabi AC, Gala JL, Horsmans Y et al. Functional impact of CYP2C9*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans. Clin Pharmacol Ther 2004 76 : 113 8.
6. Yasar U, Forslund-Bergengren C, Tybring G et al. Pharmacokinetics of losartan and its metabolite E3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 2002 71 : 89 98.
7. Sadeque AJ, Fisher MB, Korzekwa KR, Gonzalez FJ, Rettie AE. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J Pharmacol Exp Ther 1997 283 : 698 703.
8. Ho PC, Abbott FS, Zanger UM, Chang TK. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics J 2003 3 : 335 42.
9. Patsalos PN, Lascelles PT. In vitro hydroxylation of diphenylhydantoin and its inhibition by other commonly used anticonvulsant drugs. Biochem Pharmacol 1977 26 : 1929 33.
10. Kapetanovic IM, Kupferberg HJ, Porter RJ, Theodore W, Schulman E, Penry JK. Mechanism of valproate-phenobarbital interaction in epileptic patients. Clin Pharmacol Ther 1981 29 : 480 6.
11. Dhillon S, Richens A. Valproic acid and diazepam interaction in vivo. Br J Clin Pharmacol 1982 13 : 553 60.
12. Samara EE, Granneman RG, Witt GF, Cavanaugh JH. Effect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam. J Clin Pharmacol 1997 37 : 442 50.
13. Wen X, Wang JS, Kivisto KT, Neuvonen PJ, Backman JT. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol 2001 52 : 547 53.
14. Babaoglu MO, Yasar U, Sandberg M et al. CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur J Clin Pharmacol 2004 60 : 337 42.
15. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjöqvist F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999 254 : 628 31.
16. Fernandez MC, Erill S, Lucena MI, Pita E, Perez-Alferez N. Serum protein binding of tolbutamide in patients treated with antiepileptic drugs. Clin Pharmacokinet 1985 10 : 451 5.
17. Guthrie SK, Stoysich AM, Bader G, Hilleman DE. Hypothesized interaction between valproic acid and warfarin. J Clin Psychopharmacol 1995 15 : 138 9.
18. Perucca E, Hebdige S, Frigo GM, Gatti G, Lecchini S, Crema A. Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects. Clin Pharmacol Ther 1980 28 : 779 89.
19. Streetman DS, Bertino JS Jr., Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000 10 : 187 216.
20. Sekino K, Kubota T, Okada Y et al. Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur J Clin Pharmacol 2003 59 : 589 92.
21. Yasar U, Dahl ML, Christensen M, Eliasson E. Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity. Br J Clin Pharmacol 2002 54 : 183 5.